Royalty Pharma plc

RPRX

GB00BMVP7Y09

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 27/06/2024 am IST			5-day change	1st Jan Change
26.58 ^USD	-1.19%		+1.22%	-5.38%

18/06	Royalty Pharma plc Announces the Resignation of Rory Balfour Riggs as Director	CI
17/06	Royalty Pharma plc Announces Resignation of Mario Germano Giuliani as Director	CI

Royalty Pharma plc Announces the Resignation of Rory Balfour Riggs as Director

June 18, 2024 at 11:30 am IST

Royalty Pharma plc announced the resignation of Rory Balfour Riggs as director with effect from 6 June 2024.

Latest news about Royalty Pharma plc

Royalty Pharma plc Announces the Resignation of Rory Balfour Riggs as Director	18/06	CI
Royalty Pharma plc Announces Resignation of Mario Germano Giuliani as Director	17/06	CI
Transcript : Royalty Pharma plc Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02:00 PM	11/06
Royalty Pharma Prices $1.5 Billion Debt Offering	04/06	MT
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes	04/06	CI
Novartis data42 AG completed the acquisition of MorphoSys AG from group of shareholders.	30/05	CI
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	28/05	MT
Agios Pharmaceuticals to Sell 15% Vorasidenib Royalty Rights to Royalty Pharma for $905 Million	28/05	MT
Transcript : Royalty Pharma plc - Special Call	28/05
Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline	23/05	MT
Cytokinetics, Incorporated announced that it has received $49.999992 million in funding from Royalty Pharma plc	22/05	CI
Transcript : Royalty Pharma plc Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM	16/05
Transcript : Royalty Pharma plc Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 09:00 AM	14/05
Sector Update: Health Care Stocks Gain in Thursday Afternoon Trading	09/05	MT
Royalty Pharma to Acquire Frexalimab Royalties, Milestones for $525 Million in Cash	09/05	MT
Royalty Pharma's Q1 Net Income, Revenue Falls	09/05	MT
Transcript : Royalty Pharma plc, Q1 2024 Earnings Call, May 09, 2024	09/05
Earnings Flash (RPRX) ROYALTY PHARMA Reports Q1 Revenue $568M, vs. Street Est of $709.5M	09/05	MT
Royalty Pharma plc Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Arrowhead Nets $50 Milestone Payment from Royalty Pharma After Completion of Enrollment in Trial of Cardiovascular Drug	03/05	MT
Royalty Pharma Maintains Quarterly Dividend at $0.21 per Share, Payable June 14 to Shareholders of Record May 17	18/04	MT
Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024	17/04	CI
Morgan Stanley Lifts Price Target on Royalty Pharma to $46 From $44, Keeps Overweight Rating	09/04	MT
Transcript : Royalty Pharma plc Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 10:30 AM	05/03
JPMorgan Cuts Price Target on Royalty Pharma to $42 From $45, Keeps Overweight Rating	20/02	MT

Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertexâs Trikafta, GSKâs Trelegy, Rocheâs Evrysdi, Johnson & Johnsonâs Tremfya, Biogenâs Tysabri and Spinraza, AbbVie and Johnson & Johnsonâs Imbruvica, Astellas and Pfizerâs Xtandi, Novartisâ Promacta, Pfizerâs Nurtec ODT and Gileadâs Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Royalty Pharma plc

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

26.58 USD

Average target price

45 USD

Spread / Average Target

+69.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROYALTY PHARMA PLC	-5.38%	12.16B
ELI LILLY AND COMPANY	+54.61%	815B
NOVO NORDISK A/S	+44.25%	654B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+20.62%	337B
ABBVIE INC.	+10.44%	302B
ASTRAZENECA PLC	+18.45%	247B
ROCHE HOLDING AG	+2.09%	229B
NOVARTIS AG	+13.03%	219B
AMGEN INC.	+8.61%	171B

Other Pharmaceuticals